CN118251394A - 治疗性化合物 - Google Patents

治疗性化合物 Download PDF

Info

Publication number
CN118251394A
CN118251394A CN202280057092.XA CN202280057092A CN118251394A CN 118251394 A CN118251394 A CN 118251394A CN 202280057092 A CN202280057092 A CN 202280057092A CN 118251394 A CN118251394 A CN 118251394A
Authority
CN
China
Prior art keywords
alkyl
aryl
compound
heteroaryl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280057092.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·K·帕希
Y·袁
Y·张
J·罗萨多
P·达塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAXIS PHARMACEUTICALS Inc
Original Assignee
TAXIS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAXIS PHARMACEUTICALS Inc filed Critical TAXIS PHARMACEUTICALS Inc
Publication of CN118251394A publication Critical patent/CN118251394A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280057092.XA 2021-06-22 2022-06-21 治疗性化合物 Pending CN118251394A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213519P 2021-06-22 2021-06-22
US63/213,519 2021-06-22
PCT/US2022/034374 WO2022271723A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Publications (1)

Publication Number Publication Date
CN118251394A true CN118251394A (zh) 2024-06-25

Family

ID=84544904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280057092.XA Pending CN118251394A (zh) 2021-06-22 2022-06-21 治疗性化合物

Country Status (10)

Country Link
US (1) US20240317749A1 (enExample)
EP (1) EP4359416A4 (enExample)
JP (1) JP2024524213A (enExample)
KR (1) KR20240067229A (enExample)
CN (1) CN118251394A (enExample)
AU (1) AU2022297426A1 (enExample)
CA (1) CA3225427A1 (enExample)
IL (1) IL309569A (enExample)
MX (1) MX2024000022A (enExample)
WO (1) WO2022271723A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117815240A (zh) * 2023-12-11 2024-04-05 兰州大学 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436524T3 (es) * 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
BR112013008527A2 (pt) * 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US12428423B2 (en) * 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
EP4204093A1 (en) * 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Also Published As

Publication number Publication date
WO2022271723A1 (en) 2022-12-29
EP4359416A1 (en) 2024-05-01
AU2022297426A1 (en) 2024-02-01
MX2024000022A (es) 2024-03-15
JP2024524213A (ja) 2024-07-05
US20240317749A1 (en) 2024-09-26
CA3225427A1 (en) 2022-12-29
IL309569A (en) 2024-02-01
KR20240067229A (ko) 2024-05-16
EP4359416A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
US11845742B2 (en) Therapeutic compounds and methods to treat infection
KR102697360B1 (ko) 유출 펌프 억제제로서의 인돌 유도체
US9926261B2 (en) Bacterial efflux pump inhibitors
JP7281822B2 (ja) 細菌の排出ポンプ阻害剤
US9950993B2 (en) Bacterial efflux pump inhibitors
US11180459B2 (en) Bacterial efflux pump inhibitors
WO2019005841A1 (en) THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
WO2018165614A1 (en) Bacterial efflux pump inhibitors
JPH02289583A (ja) ５―アルキルキノロンカルボン酸類
US10556854B2 (en) Bacterial efflux pump inhibitors
WO2017147335A1 (en) Bacterial efflux pump inhibitors
CN104981469B (zh) 抗微生物剂
EP4359416A1 (en) Therapeutic compounds
JPH02290870A (ja) 対掌体的に純粋な７‐（３‐アミノ‐１‐ピロリジニル）‐キノロン‐および‐ナフチリドンカルボン酸
WO2021243273A1 (en) Bacterial efflux pump inhibitors
WO2025043115A1 (en) Bacterial efflux pump inhibitors
CN101450947B (zh) 7-(3-肟基-4-氨基-4-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
HK1215031B (en) Antimicrobial agents
JPS61243081A (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination